concentrated bone marrow aspirate (cBMA) in patients with CLI and poor options for revascularization. Patients were randomized in a 3:1 fashion to cBMA or placebo (sham procedure), respectively, and stratified by Rutherford score (4 or 5) and diabetes. cBMA injections or sham injections were placed below the knee at 35 to 40 sites. The primary end point was amputation-free survival (AFS) at 52 weeks; the secondary end points were incidence of major amputation, changes in ankle-brachial index, toe-brachial index, transcutaneous oxygen pressure (TcPO 2 ), 6-minute walk test (6MWT) distance, visual analog pain scale, VascuQol Questionnaire, and wound healing.
Objectives: Vascular conduit is essential for arterial reconstruction under a number of surgical conditions, including both trauma and atherosclerotic occlusive disease. We have developed a novel human tissue-engineered blood vessel for clinical investigation that can be manufactured, stored on site, and can be readily available for arterial vascular reconstruction. Preclinical and clinical testing has demonstrated that these vessels repopulate and remodel with the recipient's own vascular cells following implantation. We report on the first-in-man clinical experience of using human tissue-engineered blood vessels for arterial reconstruction in patients with symptomatic peripheral arterial occlusive disease.
Methods: Human tissue-engineered blood vessels were manufactured using human vascular smooth muscle cells on a biodegradable scaffold. Following the establishment of adequate cell growth and extracellular matrix deposition, the vessels were decellularized to remove human donor antigens. Manufactured vessels were confirmed to have suture retention and burst strength similar to or greater than human saphenous vein. These vessels were then used for first-in-man surgical implantation in 20 patients with symptomatic claudication as an above-knee, femoral-to-popliteal arterial bypass conduit. Patients were monitored for 2 years. Safety, durability, freedom from infection, and patency were all recorded.
Results: There were 20 human tissue-engineered blood vessels placed in the arterial, above-knee, femoral-to-popliteal position in patients with symptomatic claudication. All vessels functioned as intended and had no evidence of structural failure or immune recognition. No acute vessel infections were reported in any of the patients. One vessel developed a pseudoaneurysm following suspected iatrogenic injury from balloon placement. No significant wound complications were observed, and no patients required prolonged hospitalization or the wound care often associated with saphenous vein harvest. Primary unassisted patency was 58% and secondary patency was >74% at 2 years. No delayed vessel infections were reported in >40 patient-years of continuous patient follow-up.
Conclusions: Human tissue-engineered blood vessels can be manufactured and readily available for vascular surgical use. Early clinical experience with these vessels in the arterial position, suggest that they are safe, have enduring patency, have a low incidence of infection, and do not require the harvest of autologous vein. This first-in-man study supports the continued development of human tissue-engineered blood vessels for arterial reconstruction and future development of a pivotal, phase III, clinical study using this tissue as a vascular conduit for arterial disease. Objectives: Readmission rates are expected to have a growing effect on both the hospital bottom line and physician reimbursements. Safety net hospitals may be most vulnerable. We examined readmissions at 30 days, 90 days, and 1 year in a large safety net hospital because the magnitude and effect of short-and long-term readmission rates after lower extremity infrainguinal bypass (LEB) in this setting are unclear.
Methods: All LEBs performed at a large safety net hospital from 2007 to 2016, were identified. Readmissions at 30 and 90 days and 1 year were analyzed for independent predictors of readmission.
Results: There were 350 LEB performed for claudication (25.6%), rest pain (17.4%), and tissue loss (57%). Patient insurance included Medicare (61.7%), Medicaid (25.4%), and private (13%). The distal target was the popliteal artery in 52.6% and the tibial artery in 47.4%. Autologous vein was used in 73.1% of bypasses. In-hospital complications were urinary tract infection (3.1%), myocardial infarction (1.7%), surgical site infection (SSI; 1.1%), bleeding (1.4%), pulmonary (4.3%), stroke (0.9%), acute renal failure (2%), and graft occlusion (2%). Thirty-day readmission rate was 30%, and most common reasons were SSI, foot wounds, other infectious causes, congestive heart failure, and cardiac ischemia. The 90-day readmission rate was 49.4%, and most common reasons included SSI, graft complication, cardiac ischemia, contralateral leg morbidity, and gastrointestinal. Readmission within 1 year was 72.2%, and reasons included SSI, graft complication, foot wounds, contralateral leg morbidity, and other infection causes (Table) . Tibial bypass target predicted 30 day (odds ratio [OR], 1.685; 95% confidence interval [CI], 1.06-2.69; P ¼ .029) and 90 day (OR, 1.77; 95% CI, 1.14-2.74; P ¼ .011) readmission. Rest pain (OR, 2.38; 95% CI, 1.07-5.3; P ¼ .035) and nonprivate insurance (OR, 2.58; 95% CI, 1.26-5.29; P ¼ .01) predicted 1-year readmission.
Conclusions: Short-and long-term readmission rates in a safety net setting are high. Thirty-day rates are higher than historically reported rates. These data set baseline rates of 90-day and 1-year readmission
